Leukemia Research
Volume 32, Issue 9 , Pages 1472-1475, September 2008

Granulocytic sarcoma of Core-binding Factor (CBF) acute myeloid leukemia mimicking pancreatic cancer

  • Henning Sebastian Schäfer

      Affiliations

    • University of Freiburg Medical Center, Department of Hematology/Oncology, Freiburg, Germany
  • ,
  • Heiko Becker

      Affiliations

    • University of Freiburg Medical Center, Department of Hematology/Oncology, Freiburg, Germany
  • ,
  • Annette Schmitt-Gräff

      Affiliations

    • University of Freiburg, Department of Pathology, Freiburg, Germany
  • ,
  • Michael Lübbert

      Affiliations

    • University of Freiburg Medical Center, Department of Hematology/Oncology, Freiburg, Germany
    • Corresponding Author InformationCorresponding author at: Medical Center, University of Freiburg, Freiburg, Germany.

Received 22 November 2007; received in revised form 10 February 2008; accepted 10 February 2008. published online 07 March 2011.

Abstract 

Granulocytic sarcoma mimicking a synchronous second primary neoplasm (SPN) constitutes a diagnostic and therapeutic challenge particularly in elderly patients. We report on a 75-year-old female presenting with a Core-binding Factor (CBF) AML of M4eo subtype. The patient also had jaundice, highly elevated bilirubin, lipase, alkaline phosphatase (AP), CA 19-9, and a pancreatic mass highly suspicious of infiltrating pancreatic carcinoma. However, a biopsy demonstrated granulocytic sarcoma. Since the patient had no comorbidities and had been in excellent performance status until the diagnosis of AML, induction chemotherapy was initiated, with subsequent normalization of bilirubin, CA 19-9, lipase and AP. Complete hematologic remission of AML was attained and the pancreatic mass could not be detected anymore. Retrospective analysis of the c-kit protooncogene did not disclose activating mutations of exons 8 or 17. Following one consolidation treatment, the patient remained in excellent health until relapse occurred 7 months later and she succumbed to AML. In conclusion, AML can rarely mimic the clinical picture of pancreatic cancer. The initially good response of this CBF leukemia highlights the principal usefulness of aggressive induction chemotherapy also in older AML patients, if they are carefully selected not only according to biological risk factors such as cytogenetics, but also to “host factors” (good performance status, lack of comorbidities, etc.).

Keywords: Chromosomal translocations, Transcription factor, Comorbidity score, Elderly patients, Second primary neoplasms

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0145-2126(08)00081-7

doi:10.1016/j.leukres.2008.02.017

Leukemia Research
Volume 32, Issue 9 , Pages 1472-1475, September 2008